An interventional study of Aripiprazole in Schizophrenia, sponsored by Beijing HuiLongGuan Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-12-17.
Sponsored by Beijing HuiLongGuan Hospital · Not applicable, Interventional, and Treatment
Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.
Exclusion Criteria:
risperidone plus placebo
risperidone treatment plus aripiprazole 5mg/day
Drug: Aripiprazole
risperidone plus aripiprazole 10mg/day
Drug: Aripiprazole
risperidone plus aripiprazole 20mg/day
Drug: Aripiprazole
Prolactin level
Change from baseline in the levels of prolactin
Time frame: baseline, 2 weeks, 4 weeks, 8 weeks
PANSS (positive and negative syndrome scale) score
Change from baseline in PANSS score
Time frame: Baseline, 8 weeks
extrapyramidal symptoms
assess the extrapyramidal symptoms
Time frame: baseline, 4 weeks, 8 weeks
This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing HuiLongGuan Hospital